Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Get your Portfolio automatically emailed to you up to 4 times a day with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

United Community Banks Inc (UCB)

United Community Banks Inc (UCB)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
United Community Banks, Inc. Announces Quarterly Cash Dividend Approval

United Community Banks approved a quarterly cash dividend of $0.24 per share, payable January 6, 2025.Quiver AI SummaryUnited Community Banks, Inc. has announced the approval of a quarterly cash dividend...

UCB : 33.26 (+2.37%)
United Community Banks, Inc. Announces Quarterly Cash Dividend on Common and Preferred Stock

UCB : 33.26 (+2.37%)
United Community Banks: Q3 Earnings Snapshot

United Community Banks: Q3 Earnings Snapshot

UCB : 33.26 (+2.37%)
United Community Banks, Inc. Reports Third Quarter Results

UCB : 33.26 (+2.37%)
UCB announces U.S. FDA approval of ZILBRYSQ® (zilucoplan) for the treatment of adults with generalized myasthenia gravis

FDA approval of ZILBRYSQ® (zilucoplan) has been granted for the treatment of generalized myasthenia gravis (gMG) in adult patients who are anti-acetylcholine...

UCB : 33.26 (+2.37%)
UCB announces U.S. FDA approval of RYSTIGGO® (rozanolixizumab-noli) for the treatment of adults with generalized myasthenia gravis

FDA approval of RYSTIGGO® (rozanolixizumab-noli) has been granted under the Priority Review designation for the treatment of generalized myasthenia gravis...

UCB : 33.26 (+2.37%)
UCB and Ariceum Therapeutics sign a Strategic Research Collaboration to Discover New Modalities for the Treatment of Immune-related Diseases and Cancer

/PRNewswire/ -- Ariceum Therapeutics (Ariceum), a private biotech company developing radiopharmaceutical products for the diagnosis and treatment of certain...

UCB : 33.26 (+2.37%)
UCB Announces FINTEPLA® (fenfluramine) Oral Solution Is Now Descheduled and Is No Longer Listed as a Controlled Substance

/PRNewswire/ -- UCB (Euronext: UCB), a global biopharmaceutical company, today announced the U.S. Drug Enforcement Administration (DEA) has published a final...

UCB : 33.26 (+2.37%)
Epilepsia Publishes Interim Results of Open-Label Extension Study of FINTEPLA® (fenfluramine) Oral Solution in Patients with Lennox-Gastaut Syndrome (LGS)

Peer-reviewed results from the Phase 3 open-label extension study of FINTEPLA® in LGS provide significant reduction in the frequency of multiple seizure types...

UCB : 33.26 (+2.37%)
Iktos Announce Collaboration with UCB in AI for Retrosynthesis

Iktos, a company specialized in Artificial Intelligence for new drug design and UCB, a global biopharma company focusing on neurology and immunology, today announced a software licensing agreement related...

UCB : 33.26 (+2.37%)

Barchart Exclusives

ELF’s Unusual Options Activity Is a Thing of Questionable Beauty
E.L.F. Beauty’s options volume on Wednesday was 7x the 30-day average. The affordable makeup and skincare company’s unusual options activity stood out as one investor questioned its revenues. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar